MedTrace Logo

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

NCT02769832 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-07-29

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.

Conditions

  • Small Cell Lung Cancer (SCLC)

Interventions

DRUG

Nab-paclitaxel

Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Muhammad Furqan

    lead OTHER

Principal Investigators

  • Muhhamad Furqan, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-29
Primary Completion
2021-09-23
Completion
2022-07-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02769832 on ClinicalTrials.gov